Unassociated Document

-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, APMR8SiU3A4Cr4oUG4lrAVOSjvGAjhnDJdI7dy8Ffno9htoO4YL8nOgSvLGsTaE6 FPzB+pmU9pZMIWa8KWz/KA== 0000882377-06-003447.txt : 20061010 0000882377-06-003447.hdr.sgml : 20061009 20061010122006 ACCESSION NUMBER: 0000882377-06-003447 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20050404 FILED AS OF DATE: 20061010 DATE AS OF CHANGE: 20061010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CALYPTE BIOMEDICAL CORP CENTRAL INDEX KEY: 0000899426 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 061226727 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5000 HOPYARD ROAD, SUITE 480 CITY: PLEASANTON STATE: CA ZIP: 94588 BUSINESS PHONE: 9257307200 MAIL ADDRESS: STREET 1: 5000 HOPYARD ROAD, SUITE 480 CITY: PLEASANTON STATE: CA ZIP: 94588 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MARR TECHNOLOGIES BV CENTRAL INDEX KEY: 0001262853 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32280 FILM NUMBER: 061136603 BUSINESS ADDRESS: STREET 1: STRAWINSKYLAAN 1431 STREET 2: 1077XX CITY: AMSTERDAM THE NEDTHERLANDS STATE: P7 ZIP: 00000 BUSINESS PHONE: 0110031206625501 MAIL ADDRESS: STREET 1: STRAWINSKYLAAN 1431 STREET 2: 1077XX CITY: AMSTERDAM THE NETHERLANDS STATE: P7 ZIP: 00000 4 1 p06-1524_ex.xml X0202 4 2005-04-04 0 0000899426 CALYPTE BIOMEDICAL CORP CBMC 0001262853 MARR TECHNOLOGIES BV STRAWINSKYLAAN 1431 1077XX AMSTERDAM THE NEDTHERLANDS P7 NETHERLANDS 0 0 1 0 Common Stock, Anti-dilution Adjustment 2005-06-30 4 J 0 1968750 0.00 A 1968750 D Common Stock 2006-07-21 4 P 0 16964583 0.15 A 16964583 D Warrant to Purchase Common Stock 0.325 2005-04-04 4 J 0 9333333 A 2005-04-04 2010-04-03 Common Stock 9333333 0 D Warrant to Purchase Common Stock 0.325 2005-04-04 4 J 0 4200000 A 2005-04-04 2010-04-03 Common Stock 4200000 0 D Warrant to Purchase Common Stock 0.40 2005-04-04 4 J 0 500000 A 2005-04-04 2010-04-03 Common Stock 500000 0 D Convertible Notes 0.30 2005-04-04 4 J 0 2800000 A 2005-04-04 2007-04-03 Common Stock 9333333 2800000 D Warrant to Purchase Common Stock 0.325 2005-06-30 4 J 0 306250 A 2005-06-30 2009-05-28 Common Stock 9333333 0 D Warrant to Purchase Common Stock 0.45 2005-06-30 4 J 0 2625000 A 2005-06-30 2009-05-28 Common Stock 4200000 0 D Warrant to Purchase Common Stock 0.25 2006-08-03 4 J 0 8482292 A 2006-08-03 2007-08-03 Common Stock 8482292 8482292 D The direct owner is Marr Technologies BV, which is a wholly owned subsidiary of Marr Technologies NV, which is a wholly owned subsidiary of Marr Technologies Limited, which is a wholly owned subsidiary of Marr Group Holdings Limited, which is controlled by Marat R. Safin. Marr Technologies NV, Marr Technologies Limited, Marr Group Holdings Limited and Marat R. Safin are indirect beneficial owners of the reported securities. Marr Technologies BV purchased 8% convertible promissory notes of HIV, due April 3, 2007, in the aggregate principal amount of $2,800,000. These notes are convertible into common stock of HIV at an exercise price of $0.30 per share. As an inducement to purchase these notes, the Company issued Marr Technologies a warrant to purchase 9,333,333 shares of common stock of HIV and a warrant to purchase 4,200,000 shares of common stock of HIV. Marr Technologies BV was issued a warrant to purchase 500,000 shares of common stock of HIV in exhange for providing HIV a $5.5 million credit facility. Marr Technologies BV was issued 1,968,750 shares of common stock of HIV and warrants to purchase 306,250 shares of common stock of HIV as a result of certain anti-dilution provisions from an equity financing that occurred in April and July of 2004. Marr Technologies BV received this warrant to replace an existing warrant to purchase 2,625,000 shares of common stock of CYPT for $0.50 per share. Marr Technologies BV received this warrant to purchase common stock of HIV in consideration for exercising, in full, five other warrants held by Marr Technologies in HIV. Exhibit A - Joint Filer Information Christian Strik 2006-10-10 EX-99 2 p06-1524_ex99.htm JOINT FILER INFORMATION Unassociated Document

	EXHIBIT A
Form 4 Joint Filer Information


Name:	Marr Technologies NV

Address:	Van Engelenweg 21 A
	Curacao
	Netherlands Antilles

Designated Filer:	Marr Technologies BV

Issuer & Ticker Symbol:	Calypte Biomedical Corporation “HIV”

Date of Earliest Transaction
Required to be Reported:	04/04/05

Signature:	By:/s/ George Praag
	George Praag
	Director of C.T.M. Corporation N.V.




Name:	Marr Technologies Limited

Address:	Suite 240,
	Barkly Wharf,
	Le Caudan Waterfront,
	Port Louis,
	Mauritius

Designated Filer:	Marr Technologies BV

Issuer & Ticker Symbol:	Calypte Biomedical Corporation “HIV”

Date of Earliest Transaction
Required to be Reported:	04/04/05

Signature:	By: /s/ Marat R. Safin
	Marat R. Safin
	Director

EXHIBIT A


Form 4 Joint Filer Information


Name:	Marr Group Holdings Limited

Address:	Suite 240,
	Barkly Wharf,
	Le Caudan Waterfront,
	Port Louis,
	Mauritius

Designated Filer:	Marr Technologies BV

Issuer & Ticker Symbol:	Calypte Biomedical Corporation “HIV”

Date of Earliest Transaction
Required to be Reported:	04/04/05

Signature:	By: /s/ Marat R. Safin
	Marat R. Safin
	Director





Name:	Marat R. Safin

Address:	46 Clapham Common North Side
	London SW4 0AA
	United Kingdom

Designated Filer:	Marr Technologies BV

Issuer & Ticker Symbol:	Calypte Biomedical Corporation “HIV”

Date of Earliest Transaction
Required to be Reported:	04/04/05

Signature:	/s/ Marat R. Safin
	Name: Marat R. Safin

-----END PRIVACY-ENHANCED MESSAGE-----